{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:56:43Z","timestamp":1779926203456,"version":"3.53.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:p>\n                    This study aimed at evaluating prognostic factors for survival and treatment response in patients with myelodysplastic syndromes (MDS) transforming to acute myeloid leukemia (AML). This retrospective study included 182 MDS patients treated at our hospital between January 2018 and January 2023, with 52 patients transforming to AML. Patients were categorized into good and poor prognosis groups based on survival beyond 12 months. Data on baseline demographics, clinical parameters at MDS diagnosis and AML transformation, treatment response, and survival outcomes were analyzed. Multivariate Cox regression was used to identify prognostic factors. Of the 52 patients who transformed into AML, 20 were in the good prognosis group and 32 in the poor prognosis group. The mean age was 64.5\u2005\u00b1\u200510.2 years, with no significant age difference between the groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.15). Gender distribution was 57.7% male and 42.3% female. The good prognosis group had significantly lower Eastern Cooperative Oncology Group (ECOG) performance status scores (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.02). At MDS diagnosis, the poor prognosis group had worse International Prognostic Scoring System scores, higher bone marrow blast percentages, poorer cytogenetic risk, and shorter transformation time (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). At AML transformation, the poor prognosis group had higher white blood cell counts, bone marrow blast percentages, and TP53 mutation rates (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). Multivariate analysis identified ECOG score\u2005\u2265\u20052 (HR\u2005=\u20052.91,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.02), higher IPSS score (HR\u2005=\u20052.56,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.04), RAEB-1\/RAEB-2 subtypes (HR\u2005=\u20054.73,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.003), higher bone marrow blast percentage (HR\u2005=\u20051.38,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.02), TP53 mutation (HR\u2005=\u20054.92,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.01), and high-risk cytogenetic abnormalities (HR\u2005=\u20056.32,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) as independent poor prognosis factors. Treatment response analysis showed that patients in complete remission had significantly longer overall survival than those with partial remission or no response (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). The prognosis of MDS transforming into AML is influenced by factors such as ECOG performance status, IPSS score, bone marrow blast percentage, TP53 mutations, and cytogenetic risk. These findings stress the importance of early identification of high-risk patients for treatment strategies, including intensive therapies or hematopoietic stem cell transplantation. Achieving complete remission significantly improves survival outcomes, highlighting the need for optimal early treatment.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000043783","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:02:53Z","timestamp":1756494173000},"page":"e43783","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Prognosis of the transformation of myelodysplastic syndromes to acute myeloid leukemia: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"given":"Yufang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Huangshi, Hubei, China"},{"name":"Department of Rheumatology, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Huangshi, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0096-2879","authenticated-orcid":false,"given":"Jinyong","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Hematology, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review.","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries.","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-015-0489-2","article-title":"Unraveling myelodysplastic syndromes: current knowledge and future directions.","volume":"18","author":"Chamseddine","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","article-title":"Myelodysplastic syndromes.","volume":"8","author":"Li","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.2217\/fon-2022-0334","article-title":"Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.","volume":"18","author":"Kota","year":"2022","journal-title":"Future Oncol"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"101415","DOI":"10.1016\/j.beha.2022.101415","article-title":"Recent progress in acute leukemia and myelodysplasia.","volume":"35","author":"Carraway","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia.","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood.V81.11.3022.3022","article-title":"Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.","volume":"81","author":"Sugimoto","year":"1993","journal-title":"Blood"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).","volume":"35","author":"Yun","year":"2021","journal-title":"Leukemia"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes.","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"1033534","DOI":"10.3389\/fonc.2022.1033534","article-title":"Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia.","volume":"12","author":"Ambinder","year":"2022","journal-title":"Front Oncol"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.leu.2405078","article-title":"Genetics of therapy-related myelodysplasia and acute myeloid leukemia.","volume":"22","author":"Pedersen-Bjergaard","year":"2008","journal-title":"Leukemia"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/ijlh.13316","article-title":"High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome.","volume":"43","author":"Gao","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","article-title":"Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.","volume":"89","author":"Th\u00e9pot","year":"2014","journal-title":"Am J Hematol"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00277-016-2759-y","article-title":"Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.","volume":"95","author":"Lee","year":"2016","journal-title":"Ann Hematol"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.23509","article-title":"Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.","volume":"88","author":"Cluzeau","year":"2013","journal-title":"Am J Hematol"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/leu.2011.80","article-title":"Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.","volume":"25","author":"Bacher","year":"2011","journal-title":"Leukemia"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-Mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions [published correction appears in Cancer Discov. 2022 Dec 2;12(12):2954. doi: 10.1158\/2159-8290.CD-22-1192.].","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML.","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS.","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jcp.21769","article-title":"Molecular pathways mediating MDS\/AML with focus on AML1\/RUNX1 point mutations.","volume":"220","author":"Harada","year":"2009","journal-title":"J Cell Physiol"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41408-022-00748-9","article-title":"Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).","volume":"12","author":"Brunner","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:02:03Z","timestamp":1775455323000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":23,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043783","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2025-05-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}